The slowdown in developing markets has prompted many pharmaceutical firms to focus on specialty drugs according to an IMS Health analyst, who predicted that the trend will accelerate.
Quintiles has formed an alliance with information and technology provider IMS Health to access real-world drug data to be used in post-approval clinical research.
IMS Health has confirmed it is “exploring strategic alternatives” after speculation this week suggested that the market analysis group had received a number of takeover bids.
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing space, including appointments at IMS Health, CPTC and LAB Research Canada.
US pharmaceutical major Pfizer reinforced its position as the
world's largest drug company in 2002 after putting in sales of
$29.45 billion (€25.12 bn) in 2002, a hike of 11 per cent over the
prior year, according to a new analysis...
